ArticleCell death & disease2014
Direct optic nerve sheath (DONS) application of Schwann cells prolongs retinal ganglion cell survival in vivo.
Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Real-time imaging of single neuronal cell apoptosis in patients with glaucoma.Brain : a journal of neurology · 2017Trial
- Investigating the Utility of Fractal Measures as a Diagnostic for Glaucoma.Statistics in medicine · 2026Article
- Tools and Biomarkers for the Study of Retinal Ganglion Cell Degeneration.International journal of molecular sciences · 2022Review
- Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation.Current research in neurobiology · 2022Review
- Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.Frontiers in pharmacology · 2021Review
- Dynamic changes in cell size and corresponding cell fate after optic nerve injury.Scientific reports · 2020Article
- Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration.Scientific reports · 2020Article
- Peripheral nerve injury induced changes in the spinal cord and strategies to counteract/enhance the changes to promote nerve regeneration.Neural regeneration research · 2020Article
- Direct targeting of the mouse optic nerve for therapeutic delivery.Journal of neuroscience methods · 2019Article
- Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision.Neural regeneration research · 2018Review
- Review
- Annexins in Glaucoma.International journal of molecular sciences · 2018Review
- Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review.Frontiers in aging neuroscience · 2018Review
- Real-Time Imaging of Retinal Cell Apoptosis by Confocal Scanning Laser Ophthalmoscopy and Its Role in Glaucoma.Frontiers in neurology · 2018Review
- Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension.Mitochondrion · 2017Article
- Genetic rescue models refute nonautonomous rod cell death in retinitis pigmentosa.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Towards maximising information extraction from rodent models of ocular disease.Cell death & disease · 2016Article
- Automatic quantitative analysis of experimental primary and secondary retinal neurodegeneration: implications for optic neuropathies.Cell death discovery · 2016Article
- Current perspective of neuroprotection and glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Cell-based therapies are increasingly recognized as a potential strategy to treat retinal neurodegenerative disease. Their administration, however, is normally indirect and complex, often with an inability to assess in real time their effects on cell death and their migration/integration into the host retina. In the present study, using a partial optic nerve transection (pONT) rat model, we describe a new method of Schwann cell (SC) delivery (direct application to injured optic nerve sheath, SC/DONS), which was compared with intravitreal SC delivery (SC/IVT). Both SC/DONS and SC/IVT were able to be assessed in vivo using imaging to visualize retinal ganglion cell (RGC) apoptosis and SC retinal integration. RGC death in the pONT model was best fitted to the one-phase exponential decay model. Although both SC/DONS and SC/IVT altered the temporal course of RGC degeneration in pONT, SC/DONS resulted in delayed but long-lasting effects on RGC protection, compared with SC/IVT treatment. In addition, their effects on primary and secondary degeneration, and axonal regeneration, were also investigated, by histology, whole retinal counting, and modelling of RGC loss. SC/DONS was found to significantly reduce RGC apoptosis in vivo and significantly increase RGC survival by targeting secondary rather than primary degeneration. Both SC/DONS and SC/IVT were found to promote RGC axonal regrowth after optic nerve injury, with evidence of GAP-43 expression in RGC somas and axons. SC/DONS may have the potential in the treatment of optic neuropathies, such as glaucoma. We show that SC transplantation can be monitored in real time and that the protective effects of SCs are associated with targeting secondary degeneration, with implications for translating cell-based therapies to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.